MA47126A - Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 - Google Patents

Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4

Info

Publication number
MA47126A
MA47126A MA047126A MA47126A MA47126A MA 47126 A MA47126 A MA 47126A MA 047126 A MA047126 A MA 047126A MA 47126 A MA47126 A MA 47126A MA 47126 A MA47126 A MA 47126A
Authority
MA
Morocco
Prior art keywords
acetylcholin
muscarinic
receptor
positive allosteric
allosteric modulators
Prior art date
Application number
MA047126A
Other languages
English (en)
Inventor
Katrina A Bollinger
Sean R Bollinger
Rory Capstick
P Jeffrey Conn
Darren W Engers
Craig W Lindsley
Paul Spearing
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MA47126A publication Critical patent/MA47126A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047126A 2016-11-07 2017-11-07 Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 MA47126A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418663P 2016-11-07 2016-11-07

Publications (1)

Publication Number Publication Date
MA47126A true MA47126A (fr) 2019-10-30

Family

ID=62076580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047126A MA47126A (fr) 2016-11-07 2017-11-07 Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4

Country Status (7)

Country Link
US (1) US10961253B2 (fr)
EP (1) EP3558309B1 (fr)
JP (1) JP7099725B2 (fr)
CN (1) CN109862893B (fr)
BR (1) BR112018013763A2 (fr)
MA (1) MA47126A (fr)
WO (1) WO2018085808A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190446A1 (es) 2016-06-22 2019-03-29 Univ Vanderbilt Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN109863139B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
JP2023534803A (ja) * 2020-07-15 2023-08-14 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリン受容体ｍ４の陽性アロステリック調節因子としての７－（ピペリジン－１－イル）－４ｈ－ピリミド［１，２－ｂ］ピリダジン－４－オン誘導体
WO2023114224A1 (fr) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU2001279050B2 (en) 2000-07-27 2006-10-19 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
PE20060526A1 (es) 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
EP1619196A1 (fr) 2004-07-23 2006-01-25 Curacyte Discovery GmbH Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines et Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines substitués comme inhibiteurs de PDA-4 et/ou libération de TNF-alpha
EP1773840B1 (fr) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines et pyrido[3',2':4,5]furo[3,2-d]-pyrimidines substitués comme inhibiteurs de pda-4 et/ou libération de tnf-alpha
CA2583550C (fr) 2004-10-25 2013-05-14 Eli Lily And Company Thienopyridines potentialisateurs allosteriques du recepteur muscarinique m4
ES2259892B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
AU2007258313A1 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008083356A1 (fr) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Triazoles substitués utilisés comme inhibiteurs d'axl
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009151569A2 (fr) 2008-06-09 2009-12-17 Combinatorx, Incorporated Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b
AU2010286168B2 (en) 2009-08-20 2014-05-15 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
WO2012131297A1 (fr) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Dérivés de pyrido[3',2':4,5]thiéno[3,2-d]pyrimidin-4-ylamine et leur utilisation thérapeutique
US9056876B2 (en) 2011-09-16 2015-06-16 Vanderbilt University Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
JP6473330B2 (ja) 2011-12-21 2019-02-20 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法
US8697888B2 (en) 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
ES2656972T3 (es) 2012-02-23 2018-03-01 Vanderbilt University Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4
WO2014011902A1 (fr) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
US9056875B2 (en) 2012-08-31 2015-06-16 Vanderbilt University Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US9637498B2 (en) 2013-08-23 2017-05-02 Vanderbilt University Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2015200619A1 (fr) 2014-06-26 2015-12-30 Rodin Therapeutics, Inc. Inhibiteurs d'histone désacétylase
PE20190446A1 (es) * 2016-06-22 2019-03-29 Univ Vanderbilt Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
CN109863139B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Also Published As

Publication number Publication date
WO2018085808A1 (fr) 2018-05-11
US20190330225A1 (en) 2019-10-31
EP3558309A1 (fr) 2019-10-30
CN109862893B (zh) 2023-02-17
CN109862893A (zh) 2019-06-07
JP7099725B2 (ja) 2022-07-12
EP3558309A4 (fr) 2020-07-01
EP3558309B1 (fr) 2023-07-26
BR112018013763A2 (pt) 2018-12-11
US10961253B2 (en) 2021-03-30
JP2019537590A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
MA45463A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA44253A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
DK3452448T3 (da) Modulatorer af den integrerede stressvej
MA46722A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
MA47126A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
MA43756A (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
PT3452454T (pt) Moduladores da via integrada ao stresse
MA47127A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
IL264951B (en) Positive allosteric modulators of the m1 muscarinic receptor
MA46899A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
MA44236A (fr) Anticorps anti-tgfbêta 2
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
MA52555A (fr) Modulateurs du récepteur des oestrogènes
HUE036698T2 (hu) Mérõeszközök regisztrálása az interneten keresztül
MA51036A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA51037A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
IT201700039369A1 (it) Dispositivo per il calcolo dell'indice bispettrale
UA36196S (uk) Тяга верхня навісного пристрою транспортного засобу
ES1184294Y (es) Tapón vertedor antigoteo
ITUA20163954A1 (it) "integrazione dell'ordine logico"
UA34712S (uk) Дюбель-хомут «вертоліт» для кріплення кабелю
FR3045913B1 (fr) Element pour la construction d'un module d'harmonica
UA34620S (uk) Іграшка - конструктор «мост»
FI11253U1 (fi) Kolmijalka